Lv3
300 积分 2024-12-10 加入
Correction: Economic evaluation of atezolizumab in combination with bevacizumab and chemotherapy for metastatic, persistent, or recurrent cervical cancer in China: A cost-effectiveness analysis
22天前
已完结
Ivonescimab versus pembrolizumab for PD-L1-positive non-small cell lung cancer (HARMONi-2): a randomised, double-blind, phase 3 study in China
1个月前
已完结
Ivonescimab plus chemotherapy versus tislelizumab plus chemotherapy in advanced squamous non-small-cell lung cancer (HARMONi-6): interim overall survival analysis of a randomised, double-blind, phase 3 trial in China
1个月前
已完结
Ivonescimab plus chemotherapy versus tislelizumab plus chemotherapy in advanced squamous non-small-cell lung cancer (HARMONi-6): interim overall survival analysis of a randomised, double-blind, phase 3 trial in China
1个月前
已完结
Tiragolumab plus atezolizumab and chemotherapy as first-line treatment for patients with unresectable oesophageal squamous cell carcinoma (SKYSCRAPER-08): a randomised, double-blind, placebo-controlled, phase 3 trial
1个月前
已完结
Datopotamab deruxtecan in patients with untreated, advanced triple-negative breast cancer (TROPION-Breast02): a randomised, open-label, international, phase III trial
1个月前
已完结
First-Line Zongertinib in Advanced HER2 -Mutant Non–Small-Cell Lung Cancer
1个月前
已完结
Pharmacoeconomic evaluation for Chinese medicine products: Progress, challenges, and suggestions
1个月前
已完结
Improved clinical outcomes with low-dose anti-CTLA-4 (Nurulimab) plus anti-PD-1 (Prolgolimab) vs. anti-PD-1 monotherapy in advanced cutaneous melanoma: Results from the phase III OCTAVA trial
1个月前
已完结
Pembrolizumab vs cemiplimab for the treatment of advanced non-small cell lung cancer with PD-L1 expression levels of at least 50%: A network meta-analysis and cost-effectiveness analysis
1个月前
已完结
皖公网安备34019202002308
